Human DR4 antibodies and uses thereof
AssigneeGenentech, Inc.
InventorsAnan Chuntharapai, Kyung Jin Kim
Life of this patent
Estimating the term…
Abstract
Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
Claims27
An isolated, monoclonal human anti-DR4 receptor antibody that inhibits binding of Apo-2 ligand to the DR4 receptor, induces apoptosis upon binding to the DR4 receptor and binds to the same DR4 receptor epitope to which the monoclonal antibody produced by the hybridorna deposited as ATCC PTA-3359 binds, wherein said antibody binds to the DR4 receptor with a binding affinity of at least 10−8 M−1 to 10−12 M−1.
The hybridoma deposited as ATCC PTA-3359.
The monoclonal antibody produced by the hybridoma deposited as ATCC PTA-3359.
An isolated monoclonal human anti-DR4 receptor antibody that inhibits binding of Apo-2 ligand to the DR4 receptor, induces apoptosis upon binding to DR4 receptor, and binds to the same DR4 receptor epitope to which the monoclonal antibody produced by the hybridoma deposited as ATCC PTA-3360 binds, wherein said antibody binds to the DR4 receptor with a binding affinity of at least 10−8 M−1 to 10−12 M−1.
The hybridoma deposited as ATCC PTA-3360.
The monoclonal antibody produced by the hybridoma deposited as ATCC PTA-3360.
An isolated monoclonal human anti-DR4 receptor antibody that inhibits binding of Apo-2 ligand to the DR4 receptor, induces apoptosis upon binding to the DR4 receptor and binds to the same DR4 receptor epitope to which the monoclonal antibody produced by the hybridoma deposited as ATCC PTA-3361 binds, wherein said antibody binds to the DR4 receptor with a binding affinity of at least 10−8 M−1 to 10−12 M−1.
The hybridoma deposited as ATCC PTA-3361.
The monoclonal antibody produced by the hybridoma deposited as ATCC PTA-3361.
Dependencies are inferred from the claim text.